Browsing Tag
gastrointestinal stromal tumor
6 posts
Cogent Biosciences posts Q3 2025 results with $430m cash and pivotal trial momentum
Find out how Cogent Biosciences is using its $430 million cash runway and regulatory momentum to drive late-stage trials and pipeline expansion in 2025.
Innovent Biologics’ olverembatinib gets Chinese breakthrough therapy status in SDH-deficient GIST
Innovent Biologics has been granted breakthrough therapy designation (BTD) for olverembatinib from the Center for Drug Evaluation (CDE)…
CHMP adopts positive opinion for avapritinib for PDGFRA D842V mutant GIST
US precision therapy company Blueprint Medicines said that the Committee for Medicinal Products for Human Use (CHMP) of…
Unum Therapeutics acquires kinase inhibitors developer Kiq
Unum Therapeutics, a US biopharma company, has acquired Kiq, a biotech company focused on the discovery and development…
Deciphera gets Qinlock FDA approval for fourth-line advanced GIST
Qinlock FDA approval : Deciphera Pharmaceuticals has been granted approval from the US Food and Drug Administration (FDA)…
FDA rejects Blueprint’s NDA for AYVAKIT for treatment of fourth-line GIST
Blueprint Medicines said that the US Food and Drug Administration (FDA) has rejected its new drug application (NDA)…